Albendazole in neurocysticercosis.

Abstract

BACKGROUND:

In India, parenchymatous cysticercus cysts are more common than the meningeal racemose variety which are seen frequently in Latin America. Reports from Mexico suggest that albendazole is effective in the treatment of neurocysticercosis. We, therefore, studied whether this drug changed the natural course of neurocysticercosis in India.

METHODS:

In a randomized, double-blind, placebo controlled study, we allocated 29 consecutive patients (22 men and 7 women) with multiple cystic lesions on computed tomography (CT) of the head suggestive of cysticercosis to 7 days treatment with albendazole (15 mg/kg/day) or placebo. CT scans were repeated at the end of treatment and 1 and 3 months later to assess the number of cysts and extent of oedema.

RESULTS:

Sixteen patients received albendazole and 13 placebo. No change was seen at the end of one week. At 3 months, 14 patients in the albendazole group and 10 in the placebo group showed more than 25% reduction in the number of lesions. The difference between the two groups was not significant.

CONCLUSION:

Albendazole given in a dose of 15 mg/kg/day for 1 week does not change the natural course of neurocysticercosis.

• Authors: M V Padma, M Behari, N K Misra, G K Ahuja
• Journal: The National medical journal of India (Natl Med J India) 1995 Nov-Dec Vol. 8 Issue 6 Pg. 255-8 ISSN: 0970-258X [Print] India
• PMID: 8520442 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Anthelmintics
• Albendazole

Topics

• Adolescent
• Adult
• Albendazole (therapeutic use)
• Anthelmintics (therapeutic use)
• Brain Diseases (drug therapy)
• Child
• Cysticercosis (drug therapy)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged